- Home
- Publications
- Publication Search
- Publication Details
Title
A brief history of melanoma
Authors
Keywords
-
Journal
MELANOMA RESEARCH
Volume 22, Issue 2, Pages 114-122
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2012-03-06
DOI
10.1097/cmr.0b013e328351fa4d
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
- (2011) J Lin et al. BRITISH JOURNAL OF CANCER
- Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A
- (2011) Imanol Arozarena et al. CANCER CELL
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Immunotherapy for melanoma
- (2011) Jeffrey Weber CURRENT OPINION IN ONCOLOGY
- Melanocortin MC1 receptor in human genetics and model systems
- (2011) Kimberley A. Beaumont et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
- (2011) Satoru Yokoyama et al. NATURE
- Ipilimumab
- (2011) Vernon K. Sondak et al. NATURE REVIEWS DRUG DISCOVERY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted therapies of gastrointestinal stromal tumors (GIST)—The next frontiers
- (2010) Stefan Duensing et al. BIOCHEMICAL PHARMACOLOGY
- A Mouse Model of Melanoma Driven by Oncogenic KRAS
- (2010) C. Milagre et al. CANCER RESEARCH
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy
- (2010) Keiran S.M. Smalley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
- (2010) S. Whittaker et al. Science Translational Medicine
- Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy
- (2009) K. S.M. Smalley et al. CANCER RESEARCH
- Rnd3 Regulation of the Actin Cytoskeleton Promotes Melanoma Migration and Invasive Outgrowth in Three Dimensions
- (2009) R. M. Klein et al. CANCER RESEARCH
- The History and Future of Chemotherapy for Melanoma
- (2009) Arvin S. Yang et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations
- (2009) Braslav Jovanovic et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
- (2009) Keiran S.M. Smalley JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A comprehensive catalogue of somatic mutations from a human cancer genome
- (2009) Erin D. Pleasance et al. NATURE
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
- (2008) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
- Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
- (2008) Robert A. Cartlidge et al. Pigment Cell & Melanoma Research
- Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
- (2008) Jose Lutzky et al. Pigment Cell & Melanoma Research
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improving Melanoma Classification by Integrating Genetic and Morphologic Features
- (2008) Amaya Viros et al. PLOS MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started